Menu
Menu
Over the last 20 years, targeted compounds have been proven effective for non-small cell lung cancer (NSCLC patients), but recent scientific breakthroughs have made immunotherapies a new pillar of cancer care. These recent advances, coupled with the avalanche of health data, have made it hard for medical professionals to identify the patient sub-groups that will benefit the most from immunotherapy, alone or in combination with chemotherapy, without experiencing significant side effects.
By using deep learning and artificial intelligence frameworks to integrate multiple biomarkers, SOPHiA GENETICS’ DEEP-Lung-IV study (NCT04994795) aims to improve the accuracy of prognosis and first-line treatment planning. Join us to discover how this study is helping medical researchers integrate different health data modalities in a meaningful way, breaking through data silos and expanding the power and reach of collective intelligence in healthcare.
As one of the Principal Investigators of the DEEP-Lung-IV Study (NCT04994795), Dr. Akerley will share his perspective on lung cancer care and his long-term vision for multimodal data integration in clinical routine.
About DEEP-Lung-IV: DEEP-Lung-IV is a multicentric observational study leveraging the power of machine learning to integrate different data modalities and understand the prognosis and treatment responses of patients diagnosed with stage IV non-small cell lung cancer.
Speakers
Jeff Gaudet, PhD
Medical Science Liaison, SOPHiA GENETICS
Wallace L. Akerley, MD
Medical Oncologist, Huntsman Cancer Institute - University of Utah Hospital
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
